Houston, (August 30, 2006) CytoGenix, Inc. (CYGX.OB) announced today that its President Chairman and CEO, Dr. Malcolm Skolnick is a featured speaker at the Life Sciences Intellectual Property Summit to be held in Philadelphia on September 27 and 28, 2006. The meeting is organized by the World Research Groups.
Conference organizers seek to showcase strategic ways in which life sciences intellectual property professionals and senior biotechnology executives position their patents to meet company objectives and impact bottom-line performance. Drawing on real-world experiences of experts in the field, the conference offers insights and strategies for life sciences firms to preserve IP value and reduce delays in bringing a product to market. Speakers include leaders from Pfizer, Novartis and Eli Lilly.
"Managing intellectual property is vital to success and survival in the biotechnology and pharmaceutical industries. The conference emphases on leveraging patent life exclusivity to get ROI on research and development, understanding the regulatory climate of biotech and pharmaceutical companies, licensing products and the impact of technology transfer and partnering with other organizations to commercialize products are drawn from the critical business factors biotechnology executives must evaluate as their companies progress," commented Dr. Skolnick.
About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA _expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix is the recipient of the 2006 Frost & Sullivan Technology Innovation award for biotechnology processing, and has one issued US patent and 43 international or US pending patent applications claiming methods and materials in connection with these platform technologies.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the website at www.cytogenix.com.
Contact: Frank Vazquez (713) 789-0070.
